Dr. Reddy’s launches RGenX to enter trade generics business in India
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, has announced its entry into the trade generics business in India with the launch of a dedicated division called ‘RGenX’.
The introduction of this division aims to provide patients in India with a broader range of affordable pharmaceutical products. By venturing into the trade generics segment, Dr. Reddy’s Laboratories reaffirms its commitment to reaching over 1.5 billion patients by 2030.
Dr. Reddy’s Laboratories plans to roll out its trade generics across various cities and towns in India, including rural areas. The company will work closely with its channel partners to ensure the availability of its products, thereby maximizing their reach to patients in need.
Dr. Reddy’s Laboratories aims to reach over 1.5 billion patients by 2030 with trade generics expansion. Photo courtesy of Arichuvadi/Wikimedia Commons.
M.V. Ramana — Dr Reddy’s Laboratories CEO of India and Emerging Markets said: “We continue to strengthen our branded generics business in India by growing brands, new product launches, productivity enhancement through digital and analytics, and select strategic acquisitions.
“We are exploring strategic collaborations in India, and investing in innovative healthcare spaces that we see as future growth drivers. This foray into trade generics will add to our reach and depth by making high-quality medicines of Dr. Reddy’s accessible to more patients around the country in keeping with our purpose of ‘Good Health Can’t Wait’.”
Dr. Reddy’s Laboratories entry into the trade generics business signifies a significant step forward in their mission to provide affordable healthcare solutions to a larger population in India. With the launch of ‘RGenX’, the company is well-positioned to enhance patient access to quality medicines and contribute to the improvement of healthcare outcomes across the nation.